How have ORMP shares performed in 2024?

Oramed Pharmaceuticals' stock was trading at $2.31 at the beginning of 2024. Since then, ORMP shares have decreased by 1.7% and is now trading at $2.27. View the best growth stocks for 2024 here .

Are investors shorting Oramed Pharmaceuticals?

Oramed Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 583,900 shares, an increase of 20.6% from the March 15th total of 484,000 shares. Based on an average daily volume of 174,600 shares, the days-to-cover ratio is currently 3.3 days. View Oramed Pharmaceuticals' Short Interest .

When is Oramed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ORMP earnings forecast .

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) issued its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN) , Sarepta Therapeutics (SRPT) , Zynerba Pharmaceuticals (ZYNE) , Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , DURECT (DRRX) , OPKO Health (OPK) , Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN) .

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free ORMP Stock Alerts

$2.27

+0.07 (+3.18%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.18
▼
$2.30
50-Day Range: $2.20
▼
$3.58
52-Week Range: $1.67
▼
$5.25

Volume: 113,647 shs
Average Volume: 171,347 shs
Market Capitalization: $91.98 million

P/E Ratio: 16.21
Dividend Yield: N/A
Price Target: N/A

Get Oramed Pharmaceuticals alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

ORMP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ORMP Stock News Headlines

March 16, 2024 | finance.yahoo.com

ORMP Apr 2024 2.500 put

March 9, 2024 | finance.yahoo.com

Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

February 21, 2024 | msn.com

Oramed to reinitiate pivotal type 2 diabetes trial after Phase III flop

February 20, 2024 | finanznachrichten.de

Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders

February 20, 2024 | prnewswire.com

Oramed Letter to Shareholders

January 24, 2024 | finance.yahoo.com

ORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery Platform

November 28, 2023 | msn.com

Oramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

November 2, 2023 | msn.com

Oramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21

October 6, 2023 | finance.yahoo.com

Oramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year ago

September 21, 2023 | finance.yahoo.com

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

August 2, 2023 | finance.yahoo.com

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

July 25, 2023 | jp.reuters.com

Oramed Pharmaceuticals, Inc.

June 20, 2023 | finance.yahoo.com

Oramed to Present at the 83rd American Diabetes Association Conference

June 17, 2023 | finance.yahoo.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 30, 2023 | finance.yahoo.com

ORMP: Advancing Development Efforts in China

May 24, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Hold Rating for Oramed Pharm (ORMP)

May 18, 2023 | msn.com

Canaccord Genuity Maintains Oramed Pharmaceuticals (ORMP) Hold Recommendation

May 18, 2023 | finance.yahoo.com

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

May 16, 2023 | msn.com

Oramed Surges on New Diabetes Treatment

May 15, 2023 | msn.com

Why Oramed Pharmaceuticals Shares Are Trading Higher Today

May 15, 2023 | finance.yahoo.com

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

May 3, 2023 | msn.com

Investing millions, Ben Shapiro joins board of Oramed Pharmaceuticals

May 2, 2023 | marketwatch.com

8-K: ORAMED PHARMACEUTICALS INC.

May 2, 2023 | finance.yahoo.com

Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company

May 1, 2023 | finance.yahoo.com

Oramed Appoints Ben Shapiro to its Board of Directors

See More Headlines

Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ORMP
CUSIP: N/A
CIK: 1176309
Web: www.oramed.com
Phone: (844) 967-2633
Fax: 972-2566-0004
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.14
Trailing P/E Ratio: 16.21
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $5.53 million
Net Margins: N/A
Pretax Margin: 379.70%
Return on Equity: -7.15%
Return on Assets: -5.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.06
Quick Ratio: 3.06

Sales & Book Value

Annual Sales: $1.34 million
Price / Sales: 68.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.04 per share
Price / Book: 0.56

Miscellaneous

Outstanding Shares: 40,520,000
Free Float: 35,657,000
Market Cap: $91.98 million
Optionable: Optionable
Beta: 1.81

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Nadav Kidron Esq. (Age 50)
President, CEO & Executive Chairman
Comp: $754.3k
Mr. David Silberman CPA (Age 40)
CFO & Treasurer
Comp: $259.53k
Dr. Miriam Kidron Ph.D. (Age 84)
Chief Scientific Officer & Director
Comp: $503.95k
Mr. Joshua Hexter (Age 54)
Chief Operating & Business Officer
Comp: $326.94k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ORMP Stock Analysis - Frequently Asked Questions

How have ORMP shares performed in 2024?: Oramed Pharmaceuticals' stock was trading at $2.31 at the beginning of 2024. Since then, ORMP shares have decreased by 1.7% and is now trading at $2.27.
View the best growth stocks for 2024 here.
Are investors shorting Oramed Pharmaceuticals?: Oramed Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 583,900 shares, an increase of 20.6% from the March 15th total of 484,000 shares. Based on an average daily volume of 174,600 shares, the days-to-cover ratio is currently 3.3 days.
View Oramed Pharmaceuticals' Short Interest.
When is Oramed Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ORMP earnings forecast.
How were Oramed Pharmaceuticals' earnings last quarter?: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) issued its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04.

What other stocks do shareholders of Oramed Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).
How do I buy shares of Oramed Pharmaceuticals?: Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORMP) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

ORMP Stock Price History

ORMP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ORMP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info